Research programme: cancer therapeutics - Apceth/University of CologneAlternative Names: CART cells - Apceth/University of Cologne; Genetically-modified mesenchymal stem cells - Apceth/University of Cologne; gmMSCs - Apceth/University of Cologne
Latest Information Update: 04 Aug 2015
At a glance
- Originator Apceth; University of Cologne
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action Cell replacements; Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer